SARS-CoV-2 whole genome sequencing
This study aims to generate high-quality whole-genome SARS-CoV-2 sequences from clinical samples collected longitudinally in participants enrolled in the Synairgen clinical trial evaluating inhaled interferon beta-1a. The sequencing data are used to characterize viral genetic diversity, within-host evolution, and changes in viral populations over the course of infection and treatment. These data support analyses of whether antiviral therapy influences viral clearance, mutation patterns, or the emergence of minority variants during acute infection. Public deposition of these sequences in the Sequence Read Archive enables independent validation of findings and facilitates comparative analyses across therapeutic studies, contributing to a deeper understanding of host-directed antiviral interventions and SARS-CoV-2 evolution.